Sunshine Biopharma Gross Profit vs. Net Income

SBFM Stock  USD 2.75  0.04  1.48%   
Based on the key profitability measurements obtained from Sunshine Biopharma's financial statements, Sunshine Biopharma may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Sunshine Biopharma's ability to earn profits and add value for shareholders.
 
Gross Profit  
First Reported
2015-06-30
Previous Quarter
2.3 M
Current Value
2.8 M
Quarterly Volatility
937 K
 
Yuan Drop
 
Covid
As of the 14th of December 2024, Price To Sales Ratio is likely to drop to 0.26. In addition to that, Days Sales Outstanding is likely to drop to 36.73. At this time, Sunshine Biopharma's Accumulated Other Comprehensive Income is very stable compared to the past year. As of the 14th of December 2024, Income Tax Expense is likely to grow to about 414.9 K, while Income Before Tax is likely to drop (4.3 M).
For Sunshine Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sunshine Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sunshine Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sunshine Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sunshine Biopharma over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(127.90)
Revenue Per Share
197.42
Quarterly Revenue Growth
0.416
Return On Assets
(0.11)
Return On Equity
(0.18)
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Sunshine Biopharma Net Income vs. Gross Profit Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Sunshine Biopharma's current stock value. Our valuation model uses many indicators to compare Sunshine Biopharma value to that of its competitors to determine the firm's financial worth.
Sunshine Biopharma is rated below average in gross profit category among its peers. It is rated below average in net income category among its peers . At this time, Sunshine Biopharma's Gross Profit is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Sunshine Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Sunshine Net Income vs. Gross Profit

Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Sunshine Biopharma

Gross Profit

 = 

Revenue

-

Cost of Revenue

 = 
1.7 M
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Sunshine Biopharma

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(4.51 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.

Sunshine Net Income Comparison

Sunshine Biopharma is currently under evaluation in net income category among its peers.

Sunshine Biopharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Sunshine Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sunshine Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Sunshine Biopharma's change in net profit over the period of time. It can combine multiple indicators of Sunshine Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income696.1 K730.9 K
Operating Income-4.8 M-4.5 M
Income Before Tax-4.1 M-4.3 M
Net Loss-4.5 M-4.7 M
Income Tax Expense395.2 K414.9 K
Total Other Income Expense Net674.4 K708.1 K
Net Loss-26.8 M-25.4 M
Net Loss-24.1 M-22.9 M
Net Interest Income602.3 K632.4 K
Interest Income736 K460 K
Change To Netincome21.1 M22.1 M
Net Loss(370.41)(388.93)
Income Quality 1.95  2.04 
Net Income Per E B T 1.10  0.77 

Sunshine Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Sunshine Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sunshine Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sunshine Biopharma's important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Sunshine Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Commodity Directory Now

   

Commodity Directory

Find actively traded commodities issued by global exchanges
All  Next Launch Module

Use Investing Themes to Complement your Sunshine Biopharma position

In addition to having Sunshine Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Utilities Thematic Idea Now

Utilities
Utilities Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Utilities theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Sunshine Biopharma is a strong investment it is important to analyze Sunshine Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sunshine Biopharma's future performance. For an informed investment choice regarding Sunshine Stock, refer to the following important reports:
Check out World Market Map.
To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
To fully project Sunshine Biopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Sunshine Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Sunshine Biopharma's income statement, its balance sheet, and the statement of cash flows.
Potential Sunshine Biopharma investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Sunshine Biopharma investors may work on each financial statement separately, they are all related. The changes in Sunshine Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Sunshine Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.